Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
OSWEGO, N.Y., June 29, 2026 (GLOBE NEWSWIRE) -- James A. Dowd, President and CEO of Pathfinder Bancorp, Inc., the bank holding company of Pathfinder Bank (NASDAQ: PBHC) (listing: PathBcp), has...
-
BRISBANE, Australia, June 29, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce that it has...
-
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo”...
-
ST. PETERSBURG, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”) the insurance holding company of...
-
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance...
-
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité ...
-
NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) has scheduled its second quarter 2026 financial results announcement. Who:Nasdaq’s CEO, CFO, and additional members of its senior...
-
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy...
-
LITTLE ROCK, Ark., June 29, 2026 (GLOBE NEWSWIRE) -- Bank OZK (the “Bank”) (Nasdaq: OZK) today announced that its Board of Directors has approved a stock repurchase program (the “Stock Repurchase...
-
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment...